|本期目录/Table of Contents|

[1]马茜茗,刘志峰.短链脂肪酸与非酒精性脂肪性肝病的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):383-386.[doi:10.3969/j.issn.1672-271X.2021.04.010]
　MA Xi-ming,LIU Zhi-feng.Progress on the roles of short-chain fatty acids in non-alcoholic fatty liver disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(04):383-386.[doi:10.3969/j.issn.1672-271X.2021.04.010]
点击复制

短链脂肪酸与非酒精性脂肪性肝病的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年04期
页码:
383-386
栏目:
综述
出版日期:
2021-08-10

文章信息/Info

Title:
Progress on the roles of short-chain fatty acids in non-alcoholic fatty liver disease
作者:
马茜茗; 刘志峰
作者单位：210008南京，南京医科大学附属儿童医院消化科（马茜茗、刘志峰）
Author(s):
MA Xi-ming ;  LIU Zhi-feng
(Department of Gastroenterology, Children’s Hospital of Nanjing Medical University, Nanjing 210008,Jiangsu, China)
关键词:
短链脂肪酸; 非酒精性脂肪性肝病; 肠-肝轴
Keywords:
short-chain fatty acid;  non-alcoholic fatty liver disease;  gut-liver axis
分类号:
R575.5
DOI:
10.3969/j.issn.1672-271X.2021.04.010
文献标志码:
A
摘要:
非酒精性脂肪性肝病是指除外酒精和其他明确病因引起的以肝内脂肪过度沉积为主要特征的肝脏病变，目前已成为中国第一大慢性肝病却缺乏有效的治疗方案。短链脂肪酸是肠道菌群的代谢产物，多研究认为短链脂肪酸在改善肠道损伤及减轻肝脏的脂肪变性、炎性损伤、氧化应激等方面发挥作用，从而可能延缓非酒精性脂肪性肝病的发生发展。文章主要就短链脂肪酸影响非酒精性脂肪性肝病的研究进展进行综述。
Abstract:
Non-alcoholic fatty liver disease is a series of liver diseases characterized by excessive fat deposition in the liver caused by the exclusion of alcohol and other definite causes, which has become the most common chronic liver disease in China and been short of effective treatment. Short-chain fatty acids are metabolites of intestinal flora. In recent years, it has been considered that short-chain fatty acids play a role in improving intestinal injury and reducing steatosis, inflammatory injury and oxidative stress of liver. Thus, it may delay the occurrence and development of non-alcoholic fatty liver disease. The recent research progress on the effect of short-chain fatty acids on non-alcoholic fatty liver disease is reviewed in this manuscrpit.

参考文献/References:

[1]Ebrahimzadeh LH,Ghotaslou R,Samadi KH,et al. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies[J].Eur J Clin Microbiol Infect Dis, 2020, 39: 613-627.
[2]非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.
[3]Hu J,Lin S,Zheng B,et al. Short-chain fatty acids in control of energy metabolism[J].Crit Rev Food Sci Nutr, 2018, 58: 1243-1249.
[4]高冰,于秋颖,贾海莲,等. 短链脂肪酸提取与检测的研究进展[J]. 包头医学院学报,2019,35(12):116-117.
[5]Michail S,Lin M,Frey Mark R,et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease[J].FEMS Microbiol Ecol, 2015, 91: 1-9.
[6]向谦,周婷,熊玲,等. 非酒精性脂肪肝病患者粪便中短链脂肪酸改变的临床研究[J]. 四川医学,2021,42(1):40-44.
[7]梁荫基,林琛莅,王少娜, 等.肥胖相关非酒精性脂肪性肝病防治的新靶点:短链脂肪酸及其受体信号通路的保护作用[J].重庆医科大学学报,2016,41(6):628-631.
[8]Ji Y,Yin Y,Sun LJ, et al. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement[J].Int J Mol Sci, 2020, 21(9):3066.
[9]胡琼源,任建安.中性粒细胞胞外诱捕网在脓毒症及肠屏障功能中的研究进展[J].医学研究生学报,2019,32(10):1084-1088.
[10]Arpaia N,Campbell C,Fan X,et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation[J].Nature, 2013, 504: 451-455.
[11]Wu W,Sun M,Chen F, et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43[J].Mucosal Immunol, 2017, 10: 946-956.
[12]Singh N,Gurav A,Sivaprakasam S,et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis[J].Immunity, 2014, 40: 128-139.
[13]Feng Y,Wang Y,Wang P, et al. Short-Chain Fatty Acids Manifest Stimulative and Protective Effects on Intestinal Barrier Function Through the Inhibition of NLRP3 Inflammasome and Autophagy[J].Cell Physiol Biochem, 2018, 49: 190-205.
[14]Sacco P,Decleva E,Tentor F,et al. Butyrate-Loaded Chitosan/Hyaluronan Nanoparticles: A Suitable Tool for Sustained Inhibition of ROS Release by Activated Neutrophils[J].Macromol Biosci, 2017, 17(11). doi: 10.1002/mabi.201700214.
[15]Glueck B,Han Y,Cresci GAM,Tributyrin Supplementation Protects Immune Responses and Vasculature and Reduces Oxidative Stress in the Proximal Colon of Mice Exposed to Chronic-Binge Ethanol Feeding[J].J Immunol Res, 2018, 2018: 9671919.
[16]Gao Y,Davis B,Zhu W,et al. Short-chain fatty acid butyrate, a breast milk metabolite, enhances immature intestinal barrier function genes in response to inflammation in vitro and in vivo[J].Am J Physiol Gastrointest Liver Physiol, 2021, 320: G521-G530.
[17]Miao W,Wu X,Wang K,et al. Sodium Butyrate Promotes Reassembly of Tight Junctions in Caco-2 Monolayers Involving Inhibition of MLCK/MLC2 Pathway and Phosphorylation of PKCβ2[J].Int J Mol Sci, 2016, 17(10):1696.
[18]Kelly CJ,Zheng L,Campbell EL,et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function[J].Cell Host Microbe, 2015, 17: 662-671.
[19]Feng Y,Wang Y,Wang P,et al. Short-Chain Fatty Acids Manifest Stimulative and Protective Effects on Intestinal Barrier Function Through the Inhibition of NLRP3 Inflammasome and Autophagy[J].Cell Physiol Biochem, 2018, 49: 190-205.
[20]Dalile B,Van Oudenhove L,Vervliet B,et al. The role of short-chain fatty acids in microbiota-gut-brain communication[J].Nat Rev Gastroenterol Hepatol, 2019, 16: 461-478.
[21]Coppola S,Avagliano C,Calignano A,et al. The Protective Role of Butyrate against Obesity and Obesity-Related Diseases[J].Molecules, 2021,26(3):682.
[22]Zhou D,Chen YW,Zhao ZH,et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression[J].Exp Mol Med, 2018, 50: 1-12.
[23]李丹丹,刘扬,韩家凯, 等.GLP-1对非酒精性脂肪肝大鼠肝脏脂肪变性的影响[J].河南医学研究,2020,29(3):385-389.
[24]Chambers ES,Byrne CS,Rugyendo A,et al. The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease[J].Diabetes Obes Metab, 2019, 21: 372-376.
[25]Safari Z,Gérard P,The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)[J].Cell Mol Life Sci, 2019, 76: 1541-1558.
[26]Donde H,Ghare S,Joshi-Barve S,et al. Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury[J].Cell Mol Gastroenterol Hepatol, 2020, 9: 569-585.
[27]方晶,方南元,薛博瑜.MicroRNAs在非酒精性脂肪性肝病中作用的研究进展[J].医学研究生学报,2017,30(9):977-981.
[28]Li Q,Chen H,Zhang M,et al. Altered short chain fatty acid profiles induced by dietary fiber intervention regulate AMPK levels and intestinal homeostasis[J].Food Funct, 2019, 10: 7174-7187.
[29]den Besten G,Bleeker A,Gerding A,et al. Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation[J].Diabetes, 2015, 64: 2398-2408.
[30]Du Y,Li X,Su C,et al. Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice[J].Br J Pharmacol, 2020, 177: 1754-1772.
[31]Sun B,Jia Y,Hong J,et al. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation[J].J Agric Food Chem, 2018, 66: 7633-7642.
[32]Chu H,Duan I,Yang L,et al. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease[J].Gut, 2019, 68: 359-370.
[33]Zhai S,Qin S,Li L,et al. Dietary butyrate suppresses inflammation through modulating gut microbiota in high-fat diet-fed mice[J].FEMS Microbiol Lett, 2019, 366(13):fnz153.
[34]Cresci GA,Glueck B,McMullen MR,et al. Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury[J].J Gastroenterol Hepatol, 2017, 32: 1587-1597.
[35]Engstler AJ,Aumiller T,Degen C,et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease[J].Gut, 2016, 65: 1564-1571.
[36]Sun B,Jia Y,Yang S,et al. Sodium butyrate protects against high-fat diet-induced oxidative stress in rat liver by promoting expression of nuclear factor E2-related factor 2[J].Br J Nutr, 2019, 122: 400-410.
[37]Jin CJ,Engstler AJ,Sellmann C,et al. Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation[J].Br J Nutr, 2016, 23:1-12.
[38]Roychowdhury S,Glueck B,Han Y,et al. A Designer Synbiotic Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice[J].Nutrients, 2019,11(1):97.

相似文献/References:

[1]李奕鑫,陈育霞,李勇飞,等.茵柴降脂汤治疗非酒精性脂肪性肝病临床疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2014,16(03):273.[doi:10.3969/j.issn.1672-271X.2014.03.015]
　LI Yi-xin,CHEN Yu-xia,LI Yong-fei,et al.The clinical observation about Yin Chai Jiang Zhi Tang decoction on patients with nonalcoholic fatty liver disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(04):273.[doi:10.3969/j.issn.1672-271X.2014.03.015]
[2]杨小骏,张海,金华.阻塞性睡眠呼吸暂停与非酒精性脂肪性肝病的关系研究[J].医学研究与战创伤救治(原医学研究生学报),2014,16(04):385.[doi:10.3969/j.issn.1672-271X.2014.04.016]
　YANG Xiao-jun,ZHANG Hai,JIN Hua..Research between obstructive sleep apnea and nonalcoholic fatty liver disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(04):385.[doi:10.3969/j.issn.1672-271X.2014.04.016]
[3]刘亚贤,温雪,袁倩倩,等.部队官兵非酒精性脂肪性肝病的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(5):514.[doi:10.3969/j.issn.1672-271X.2022.05.014]
　LIU Ya-xian,WEN Xue,YUAN Qian-qian,et al.Research progress of non-alcoholic fatty liver disease among officers and men of the army[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(04):514.[doi:10.3969/j.issn.1672-271X.2022.05.014]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81570470）；南京医科大学专病队列培育项目（NMUC2020044）
更新日期/Last Update: 2021-08-10